Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2024 Featuring 100+ Companies and 110+ Pipeline Drugs Including Lanifibranor (Inventiva Pharma), MSDC-0602K (Cirius Therapeutics), TERN-501 (Terns Pharma)
May 02, 2024 07:25 ET
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
Japan Non-Alcoholic Steatohepatitis (NASH) Market Forecast 2023-2032: Emerging Therapies & Treatment Insights, Comprehensive Market Outlook, Expert & Qualitative Analyses
January 30, 2024 07:09 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Japan Non-Alcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2032" report has been added to ...
Global Non-alcoholic Steatohepatitis (NASH) Market 2021-2038: Increased Competition from New Product Launches will Shape the NASH Market
March 23, 2021 08:08 ET
|
Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038" report has been added to ResearchAndMarkets.com's offering. There are...